LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 1 of total 1

Search options

Article ; Online: First-line therapy with palbociclib in patients with advanced HR

Martínez-Jañez, N / Ezquerra, M Bellet / Manso Sanchez, L M / Carrasco, F Henao / Torres, A Anton / Morales, S / Ortega, P Tolosa / Gil, V L Obadia / Sampedro, T / Conejero, R Andrés / Calvo-Martinez, L / Galve-Calvo, E / López, R / de la Pena, F Ayala / Lopez-Tarruella, S / de Araguiz, B A Hernando Fernandez / Ruiz, L Boronat / Cardenas, T Martos / Chacon, J I /
Antón, F Moreno

Breast cancer research and treatment

2024  

Abstract: Purpose: To evaluate the efficacy and safety of first-line therapy with palbociclib in a Spanish cohort treated after palbociclib approval.: Methods: PALBOSPAIN is an observational, retrospective, multicenter study evaluating real-world patterns and ... ...

Abstract Purpose: To evaluate the efficacy and safety of first-line therapy with palbociclib in a Spanish cohort treated after palbociclib approval.
Methods: PALBOSPAIN is an observational, retrospective, multicenter study evaluating real-world patterns and outcomes with 1 L palbociclib in men and women (any menopausal status) with advanced HR
Results: A total of 762 patients were included. The median rw-PFS and OS were 24 months (95% CI 21-27) and 42 months (40-not estimable [NE]) in the whole population, respectively. By cohort, the median rw-PFS and OS were as follows: 28 (95% CI 23-39) and 44 (95% CI 38-NE) months in patients with de novo metastatic disease, 13 (95% CI 11-17) and 36 months (95% CI 31-41) in patients who experienced relapse < 12 months after the end of ET, and 31 months (95% CI 26-37) and not reached (NR) in patients who experienced relapse > 12 months after the end of ET. rw-PFS and OS were longer in patients with oligometastasis and only one metastatic site and those with non-visceral disease. The most frequent hematologic toxicity was neutropenia (72%; grade ≥ 3: 52.5%), and the most common non-hematologic adverse event was asthenia (38%).
Conclusion: These findings, consistent with those from clinical trials, support use of palbociclib plus ET as 1 L for advanced BC in the real-world setting, including pre-menopausal women and men.
Trial registration number: NCT04874025 (PALBOSPAIN). Date of registration: 04/30/2021 retrospectively registered.
Language English
Publishing date 2024-04-01
Publishing country Netherlands
Document type Journal Article
ZDB-ID 604563-7
ISSN 1573-7217 ; 0167-6806
ISSN (online) 1573-7217
ISSN 0167-6806
DOI 10.1007/s10549-024-07287-w
Shelf mark
Zs.A 1655: Show issues Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)
Database MEDical Literature Analysis and Retrieval System OnLINE

More links

Kategorien

To top